Protein kinase inhibitor

Kinnate Biopharma Inc. to Participate at the Goldman Sachs 42nd Annual Global Healthcare Conference

Retrieved on: 
Tuesday, May 25, 2021
Goldman Sachs, Subprime mortgage crisis, Cancer, Protein kinase inhibitor, Banks, Economy of New York City, Finance

Members of the Kinnate management team will also host investor meetings during the conference.

Key Points: 
  • Members of the Kinnate management team will also host investor meetings during the conference.
  • A live webcast of the Goldman Sachs presentation will be available in the Investors and Media section of the Kinnate website at www.kinnate.com .
  • A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.
  • Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.

Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting

Retrieved on: 
Thursday, May 20, 2021
Chemical compounds, Cancer treatments, Drugs, Orphan drugs, Antineoplastic drugs, Eisai, Lenvatinib, Eribulin, Halichondrin B, Pembrolizumab, Merck & Co., Protein kinase inhibitor

b'TOKYO, May 20, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data regarding its oncology pipeline and products including in-house discovered lenvatinib mesylate (multikinase inhibitor, product name: LENVIMA, "lenvatinib") and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN, "eribulin") will be presented at the American Society of Clinical Oncology (2021 ASCO Annual Meeting*), to be held virtually from June 4 to 8, 2021.\nAt this meeting, there will be an oral presentation on the analysis of health-related quality-of-life (HRQoL) (Abstract No: 4502) of the pivotal Phase 3 CLEAR Study (Study 307/KEYNOTE-581) evaluating lenvatinib in combination with pembrolizumab (product name: KEYTRUDA, "pembrolizumab"), the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) or in combination with everolimus versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma.

Key Points: 
  • b'TOKYO, May 20, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data regarding its oncology pipeline and products including in-house discovered lenvatinib mesylate (multikinase inhibitor, product name: LENVIMA, "lenvatinib") and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN, "eribulin") will be presented at the American Society of Clinical Oncology (2021 ASCO Annual Meeting*), to be held virtually from June 4 to 8, 2021.\nAt this meeting, there will be an oral presentation on the analysis of health-related quality-of-life (HRQoL) (Abstract No: 4502) of the pivotal Phase 3 CLEAR Study (Study 307/KEYNOTE-581) evaluating lenvatinib in combination with pembrolizumab (product name: KEYTRUDA, "pembrolizumab"), the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) or in combination with everolimus versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma.
  • Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.\nThis release discusses investigational compounds and investigational uses for FDA-approved products.
  • It is not intended to convey conclusions about efficacy and safety.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.\n'

Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers

Retrieved on: 
Tuesday, May 11, 2021
Tyrosine kinase receptors, ROS1, Anaplastic lymphoma kinase, Targeted therapy, Branches of biology, Protein kinase inhibitor, Kinase, Clinical medicine, Medicine, Entrectinib

b'CAMBRIDGE, Mass., May 11, 2021 /PRNewswire/ --Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the completion of a $135 million Series B financing.

Key Points: 
  • b'CAMBRIDGE, Mass., May 11, 2021 /PRNewswire/ --Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the completion of a $135 million Series B financing.
  • "With this financing, we are well positioned to efficiently advance our parallel lead programs into clinical development and to accelerate the discovery of additional novel, selective compounds to meet medical needs in treatment-resistant cancers.
  • "\nProceeds from the Series B financing will support the clinical advancement of Nuvalent\'s parallel lead programs, NVL-520 (previously NUV-520), a potential best-in-class ROS1-selective kinase inhibitor, and NVL-655 (previously NUV-655), a potential best-in-class ALK-selective kinase inhibitor.
  • "\nNuvalent, Inc. is creating precisely targeted therapies designed to overcome the limitations of existing therapies for clinically proven kinase targets for patients with cancer.

Deciphera Pharmaceuticals, Inc. to Present at the Truist Securities Life Sciences Summit

Retrieved on: 
Wednesday, April 28, 2021
Biotechnology, Pharmaceutical, Health, Protein kinase inhibitor

b'Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Truist Securities Life Sciences Summit on May 5, 2021 at 9:40 AM ET.

Key Points: 
  • b'Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Truist Securities Life Sciences Summit on May 5, 2021 at 9:40 AM ET.
  • The conference will be held in a virtual meeting format.\nA live webcast of the event will be available on the \xe2\x80\x9cEvents and Presentations\xe2\x80\x9d page in the \xe2\x80\x9cInvestors\xe2\x80\x9d section of the Company\xe2\x80\x99s website at https://investors.deciphera.com/news-events/events-presentations .
  • We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines.
  • For more information, visit https://www.deciphera.com/ or follow us on LinkedIn and Twitter (@Deciphera).\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210428005049/en/\n'

Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, April 27, 2021
Oncology, FDA, Health, Clinical trials, General Health, Pharmaceutical, Chemical compounds, Organic compounds, Lung cancer, Tyrosine kinase receptors, Cancer treatments, Chemistry, Quinazolines, Epidermal growth factor receptor, Oncogenes, Protein kinase inhibitor, Treatment of lung cancer, Tyrosine kinase inhibitor, Mobocertinib (TAK-788), the Phase 1/2 Trial, EGFR Exon20 Insertion+ mNSCLC, Takeda Pharmaceutical Company Limited, MOBOCERTINIB (TAK-788), THE PHASE 1/2 TRIAL, EGFR EXON20 INSERTION+ MNSCLC, TAKEDA PHARMACEUTICAL COMPANY LIMITED

Additional information about Takeda\xe2\x80\x99s EAP is available here .\nMobocertinib is an investigational, first-in-class, oral tyrosine kinase inhibitor (TKI) specifically designed to selectively target epidermal growth factor receptor (EGFR) Exon20 insertion mutations.

Key Points: 
  • Additional information about Takeda\xe2\x80\x99s EAP is available here .\nMobocertinib is an investigational, first-in-class, oral tyrosine kinase inhibitor (TKI) specifically designed to selectively target epidermal growth factor receptor (EGFR) Exon20 insertion mutations.
  • In 2019, the U.S. FDA granted mobocertinib Orphan Drug Designation for the treatment of lung cancer with HER2 mutations or EGFR mutations including Exon20 insertion mutations.
  • In April 2020, mobocertinib received Breakthrough Therapy Designation from the FDA for patients with EGFR Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC) whose disease has progressed on or after platinum-based chemotherapy.
  • In this press release, \xe2\x80\x9cTakeda\xe2\x80\x9d is sometimes used for convenience where references are made to Takeda and its subsidiaries in general.

Deciphera Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 4, 2021

Retrieved on: 
Tuesday, April 27, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Protein kinase inhibitor, Gastrointestinal stromal tumor, XC2

A webcast of the conference call will be available in the \xe2\x80\x9cEvents and Presentations\xe2\x80\x9d page in the \xe2\x80\x9cInvestors\xe2\x80\x9d section of the Company\xe2\x80\x99s website at https://investors.deciphera.com/news-events/events-presentations .

Key Points: 
  • A webcast of the conference call will be available in the \xe2\x80\x9cEvents and Presentations\xe2\x80\x9d page in the \xe2\x80\x9cInvestors\xe2\x80\x9d section of the Company\xe2\x80\x99s website at https://investors.deciphera.com/news-events/events-presentations .
  • We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines.
  • In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK\xc2\xae is Deciphera\xe2\x80\x99s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumors.
  • For more information, visit https://www.deciphera.com/ or follow us on LinkedIn and Twitter (@Deciphera).\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210427005402/en/\n"

China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)

Retrieved on: 
Wednesday, March 31, 2021
Clinical medicine, Cancer treatments, Medicine, Cancer, Orphan drugs, Pyridines, Piperazines, Breakthrough therapy, Ripretinib, Imatinib, Protein kinase inhibitor

NMPAs approval of QINLOCK establishes a new standard of care for treating patients with fourth-line GIST in China.

Key Points: 
  • NMPAs approval of QINLOCK establishes a new standard of care for treating patients with fourth-line GIST in China.
  • QINLOCK may potentially alter the treatment landscape for patients in China with GIST.
  • In March 2021, the NMPA approved QINLOCK for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib.
  • QINLOCK and the QINLOCK logo are registered trademarks, and Deciphera and the Deciphera logo are trademarks, of Deciphera Pharmaceuticals, LLC.

LOU-064: An Agammaglobulinaemia Tyrosine Kinase Inhibitors Being Developed by Novartis for Sjogren's Syndrome - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 25, 2021
Health, Pharmaceutical, Novartis, Pharmaceutical companies, Protein kinase inhibitor, Tyrosine kinase, Companies, Life sciences

"LOU-064 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Sjogren's Syndrome in 7 Major Markets.

Key Points: 
  • "LOU-064 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Sjogren's Syndrome in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • LOU-064 acts as Agammaglobulinaemia tyrosine kinase inhibitors and is being developed by Novartis for Sjogren's syndrome which is currently in Phase II of clinical trial study.
  • Other emerging products for Sjogren's Syndrome are giving market competition to LOU-064 and launch of late-stage emerging therapies in the near future will significantly impact the market.

Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, March 23, 2021
Tyrosine kinase receptors, ROS1, Anaplastic lymphoma kinase, Protein kinase inhibitor, Non-small-cell lung carcinoma, Branches of biology, Clinical medicine, Targeted therapy, Medicine, ALK inhibitor

CAMBRIDGE, Mass., March 23, 2021 /PRNewswire/ --Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christopher Turner, M.D., as Chief Medical Officer.

Key Points: 
  • CAMBRIDGE, Mass., March 23, 2021 /PRNewswire/ --Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christopher Turner, M.D., as Chief Medical Officer.
  • "Chris is a dedicated physician and drug developer who has guided the early development, global registration studies, and marketing approval of multiple kinase inhibitor therapies for patients with cancer," said James Porter, Ph.D., Chief Executive Officer of Nuvalent.
  • "I am delighted to welcome him to the Nuvalent team, where his clinical vision and proven leadership will help drive the progression of our robust pipeline through multiple near-term clinical milestones."
  • Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.

Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer

Retrieved on: 
Friday, March 12, 2021
Drugs, Orphan drugs, Cancer treatments, Health sciences, Chloroarenes, Ureas, Eisai, Lenvatinib, Protein kinase inhibitor, Progression-free survival, Pembrolizumab, Clinical endpoint

TOKYO, Mar 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of Health, Labour and Welfare (MHLW).

Key Points: 
  • TOKYO, Mar 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of Health, Labour and Welfare (MHLW).
  • In this study, LENVIMA plus KEYTRUDA met its dual primary endpoints, overall survival (OS) and progression-free survival (PFS), as well as its secondary efficacy endpoint of objective response rate (ORR).
  • Currently, Eisai is preparing to submit an application for additional indications based on these results in various countries around the world including Japan.
  • Eisai positions oncology as a key therapeutic area and is aiming to discover innovative new medicines with the potential to cure cancer.